Thus, GLI inhibitors like GANT61 are advantageous in cancers where SMO contains an activating mutation or GLI activation is SHH ligand-independent and driven by e.g. KRAS mutations or by TGFβ-driven GLI2 expression [12]. The gene discussed is TGFB1; the disease is cancer.